The health of their population has always been a great concern for governments of Post-War Europe. In order to achieve their goals they had to work closely together with the pharmaceutical Industry. With the phenomenon of the aging population the importance of development of new drugs is increasing. The increasingly old population of Europe creates a big market for pharmaceutical companies. The pharmaceutical Industry is a very complex sector with close links to other Industries. The chemical Industry for example is an important supplier for materials needed in the process of creating new drugs. Furthermore is the market for pharmaceuticals characterized by extremely little concentration and a huge variety of products. Globally in 1998, the 300 best-selling products held a share of less than 45% of the worlds market. The top two products held 1.3% of the market each.1 This fact creates a necessity for the companies to research new, so called “Blockbuster drugs” to succeed on this market with a high competition. The data on the various methods of drug discovery is enormous and sophisticated. In this paper the structure of the Research & Development sector of the European pharmaceutical industry will be examined, which is of increasing importance for the success of the individual companies. The specific data on the R & D section will be given a general character. Furthermore it will give a brief overview of the different regions in Europe and their individual differences. In the end, the difficulties and challenges of R & D in the pharmaceutical industry will be described and compared to other pharma markets abroad. [1 Data taken from „Combining discovery with development” by Dr. Peter Eddershaw; World pharmaceutical frontiers 2003/2004 ]
Table of Contents
1. Introduction
2. Structure of the Research & Development of the European Pharma Industry
2.1 Clinical Trials
2.2 Outsourcing
2.2.1 Contract Research Organisations (CRO)
2.3 Company research
3. Regional R & D in Europe
3.1 Most important and effective regions in Europe
3.2 UK
3.3 Involvement of the EU
3.3.1 the EU and Clinical Trials
3.4 Central and Eastern Europe
4. Subjects of R & D
4.1 Biotechnology
4.2 issue of patents
5. Challenges for R & D of the pharmaceutical Industry of Europe
5.1 Patient recruitment
5.2 competition from abroad
6. Conclusion
7. References
Objectives and Topics
This paper examines the structure, challenges, and regional dynamics of the Research and Development (R&D) sector within the European pharmaceutical industry, aiming to understand why the region has faced a competitive decline compared to North American markets.
- The structural complexity of European pharmaceutical R&D and the role of clinical trials.
- The increasing reliance on outsourcing and Contract Research Organisations (CROs).
- Regional disparities in R&D performance and patent activity across Europe.
- The impact of EU policies and regulatory environments on drug innovation.
- Major strategic challenges, including patient recruitment difficulties and global competition.
Excerpt from the Book
Clinical Trials
In the timeline above three phases of the so called “Clinical Trials” are shown. During those a new developed drug is compared with possible alternative treatments to find out which is the best in which circumstances for which patients.
Generally they are intended to: Discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more trial products; Identify any adverse reactions to one or more such products; Study absorption, distribution, metabolism and excretion of one or more such products.
Conducting a trial includes: Administering, or giving directions for the administration for the administration of, an investigational medicinal product to a subject for purposes of that trial; Giving a prescription for an investigational medicinal product for the purposes of that trial; Carrying out any other medical or nursing procedures in relation to that trial; Carrying out any test or analysis to: Discover or verify the clinical, pharmacological or other pharmacodynamic effects of the investigational medicinal products administered in the course of the trial; Identify any adverse reactions to one or more such products; Study absorption, distribution, metabolism and excretion of those products.
Every Trial involves a sponsor, who has to take responsibility and administer the research.
Summary of Chapters
1. Introduction: Outlines the importance of the pharmaceutical industry in aging European societies and introduces the paper's goal of examining R&D structures and challenges.
2. Structure of the Research & Development of the European Pharma Industry: Details the characteristics of R&D as lengthy and costly, highlighting the growing significance of outsourcing and clinical trials.
3. Regional R & D in Europe: Analyzes the leading European nations in R&D, patent output across specific regions, and the influence of EU regulatory frameworks.
4. Subjects of R & D: Discusses the rise of biotechnology in drug development and the strategic importance of patenting as a protection mechanism.
5. Challenges for R & D of the pharmaceutical Industry of Europe: Explores hurdles like patient recruitment and the widening competitive gap between European and American pharmaceutical firms.
6. Conclusion: Summarizes the need for a more efficient, unified European market to overcome competitive disadvantages in a globalized economy.
7. References: Lists the academic articles, industry magazines, and statistical sources utilized in the research.
Keywords
Pharmaceutical Industry, Research and Development, Clinical Trials, Biotechnology, European Union, Outsourcing, Contract Research Organisations, Patenting, Patient Recruitment, Drug Discovery, Blockbuster drugs, Innovation, Competitiveness, Health Policy, Medicinal Products.
Frequently Asked Questions
What is the core focus of this research paper?
The paper focuses on the current state, structure, and challenges of the Research and Development sector within the European pharmaceutical industry.
What are the primary thematic areas covered?
Key areas include the mechanics of clinical trials, the strategic importance of outsourcing to CROs, regional R&D performance in Europe, and the ongoing struggle against global competition.
What is the ultimate research objective?
The objective is to analyze why European pharmaceutical companies are losing ground to international competitors and to evaluate potential strategies, such as creating a single European market, to stimulate innovation.
Which scientific methods are employed in this analysis?
The paper utilizes a descriptive and analytical approach, synthesizing industry statistics, reports from the European Federation of Pharmaceutical Industry Associations (EFPIA), and data from academic and professional pharmaceutical journals.
What specific issues are addressed in the main body?
The main body examines the entire R&D lifecycle—from chemical synthesis to market authorization—while specifically highlighting the shift toward outsourcing and the logistical difficulties of recruiting patients for clinical research.
Which keywords best characterize the document?
Important keywords include pharmaceutical innovation, R&D expenditure, clinical trial regulation, biopharmaceuticals, and global market competitiveness.
How do regional differences in Europe impact patent output?
The research notes a strong concentration of R&D activity in specific regions, such as Oberbayern in Germany and Noord-Brabant in the Netherlands, indicating that innovation is not evenly distributed across the EU.
Why is patient recruitment considered a major operational challenge?
Clinical trials are highly dependent on volunteer participation; factors like national holidays, clinician vacations, and competition from other studies often create "blocks" that hinder the recruitment process.
- Quote paper
- Arne Noack (Author), 2003, Research & Development of the european pharmaceutical industry, Munich, GRIN Verlag, https://www.grin.com/document/22850
